ArticleCureus2025
Development and Administration of a Skin Survey Questionnaire for Methamphetamine Users.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous complications of methamphetamine use are frequently under-recognized in clinical settings. Increased detection could facilitate the early identification of dermatologic issues and support a more holistic recovery process. This study aimed to develop and implement a skin survey questionnaire to identify common dermatologic conditions among individuals with methamphetamine use disorder. A novel skin survey was administered to 94 participants enrolled in a residential treatment program. The questionnaire included sliding-scale and dichotomous response items addressing skin appearance, symptoms, and behaviors. Participants reported a range of skin issues, including track marks (n = 21; 22.34%), hyperpigmentation (n = 18; 19.15%), and scarring (n = 16; 17.02%). Average sliding-scale scores indicated delayed wound healing (X̄ = 0.307), minimal itchiness (X̄ = 0.229), and nominal skin picking (X̄ = 0.185). Notably, 13.83% (n = 13) reported formication. Higher average skin symptom scores were significantly associated with younger age (p = 0.0499), female sex (p = 0.0462), and non-smoking routes of methamphetamine administration, particularly IV injection (p < 0.001). Duration of methamphetamine use was not significantly correlated with skin score. The survey effectively identified a variety of dermatologic symptoms associated with methamphetamine use, supporting its utility as a clinical screening tool in residential treatment settings. Further validation of the tool is recommended for broader implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.